THCB, in many posts on the subject of drug-eluting stents, has picked up on the occassional quality issues plauging both J&J’s Cypher stent and Boston Scientific’s Taxus stent in the past few months. But I must admit I didn’t expect Friday’s news of basically a virtually total recall by Boston Scientific of all its DES and some bare metal stents. (Of course if I had expected it, I’d have gone short and pocketed the $3 a share profit!).   Don’t expect drug eluting stents to exactly fall out of style. This is a production quality issue, carediologists remain sold on the value of the stents, and so are patients, even if the widespread use of DES are contributing to the financial detriment of hospitals and, eventually, Medicare and the taxpayer.